Surgeons Issue Consensus Statement on Performing Sentinel Lymph Node Biopsy

Publication
Article
OncologyONCOLOGY Vol 13 No 1
Volume 13
Issue 1

Sentinel lymph node biopsy, a minimally invasive procedure for staging patients with breast cancer, is a rapidly evolving technique in breast surgery. In response, a task force convened by the American Society of Breast Surgeons has issued a

Sentinel lymph node biopsy, a minimally invasive procedure for staging patients with breast cancer, is a rapidly evolving technique in breast surgery. In response, a task force convened by the American Society of Breast Surgeons has issued a consensus statement on performance and utilization criteria for this technique.

This statement outlines performance criteria for surgeons utilizing sentinel lymph node biopsy, identifies patients who are ineligible for the procedure, and encourages surgeons to participate in national registries and clinical trials that have been established for breast cancer lymphatic mapping. Additional information and copies of the consensus statement are available from the society at (301) 362-1722.

Dr. Michael J. Edwards, associate professor of surgery, Division of Surgical Oncology, University of Louisville, headed the task force, which included Dr. Armando E. Giuliano, chief of surgical oncology, John Wayne Cancer Institute, Santa Monica, California; Dr. Douglas Reintgen, professor of surgery, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida; and Dr. Lorraine Tafra, assistant professor of surgery, East Carolina University School of Medicine.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content